2018 LUS Annual Meeting

April 13 – 15, 2018
Loews New Orleans Hotel
New Orleans, Louisiana

Educational Needs

The field of urology covers a broad spectrum of both benign and malignant diseases of the genitourinary system. Clinical research evidence to guide the evidence-based practice of urology continues to evolve rapidly; however outside CME events, urologists have limited opportunity to familiarize themselves with evolving diagnostic and therapeutic approaches to the diseases they treat on a day-to-day basis.

The objectives of this meeting are to provide Louisiana urologists with a convenient opportunity to educate themselves about the state-of-the art management of urological diseases and engage with expert faculty. This meeting will provide urologists with an update on the latest research available to enhance their clinical practice and outcomes.

In addition, with urologists focused on the delivery of care, they cannot keep track of daily legislative and regulatory developments that will ultimately impact their provision of that care. It is important to keep urologists informed on socioeconomic activity in Washington, their state capitol and local governments, focusing on how new initiatives will impact their patients and practice. Urologists need to be aware of federal, Louisiana state and local legislation and regulations and its impact to the success of their practice and quality of patient care.

Educational Objectives

At the conclusion of the LUS 2018 Annual Meeting, attendees will be able to:

  1. Identify measurable and actionable germline mutations in prostate cancer patients.
  2. Identify measurable and actionable somatic mutations in prostate cancer.
  3. Recognize when an older patient has a clinically significant urinary tract infection.
  4. Describe mechanisms that factor in the development of urinary tract infections and strategies which may be used to prevent them.
  5. Explain how to select the appropriate candidate for varicocele repair in the era of IVF/ICSI.
  6. Discuss testosterone replacement in hypogonadism.
  7. Explain the controversy surrounding testosterone replacement therapy.
  8. Describe the various forms of testosterone replacement and deprivation.
  9. Discuss novel ways to improve outcomes in patients with high risk renal malignancies who are at high risk for recurrent or metastatic disease.
  10. Discuss optimal treatment strategies for the management of HGT1 and low-risk bladder cancer.
  11. Recognize common dermatologic conditions presenting to a Urology clinic and discuss topical medications for treatment of these conditions.
  12. Review standard treatments for BPH and their weaknesses and strengths.
  13. Describe the differences in some of the newer technologies for MIS in BPH.
  14. Strategize the appropriate BPH patient for these newer MIS.
  15. Describe the biomarkers that can be useful in prostate cancer early detection as recommended in the NCCN Guidelines.
  16. Explain the various proteomic and genomic biomarkers that can be useful in guiding shared decision making for prostate cancer patients.
  17. Describe the different genomic biomarkers that can be helpful in risk stratification and prognosis in patients with prostate cancer.
  18. Review the pathophysiology of ED following prostate surgery.
  19. Discuss treatment options for ED after RALP.
  20. Review recent options for erectile rehabilitation after NSRP highlighting patient selection and outcomes.
  21. Review current concepts of the pathophysiology of chronic pelvic pain.
  22. Discuss pain management strategies integrated into clinical management.
  23. Describe pros and cons of various options for surgically treating SUI in women.
  24. Describe the various treatment options for opioid addiction.
  25. Recognize the CDC Recommendations for the Prescription of Opioids for Chronic Pain.
  26. Explain how legislative priorities and actions may impact you and your practice.
  27. Explore the history of urethral dilation for pediatric voiding dysfunction.
  28. Implement pediatric urology treatment plans inclusive of surgical and nonsurgical options.
  29. Define ogliometastatic disease.
  30. Review case based scenarios of ogliometastatic prostate cancer directed learning based on current evidence-based literature.
  31. Recognize the new GU cancer imaging modalities and identify the patients which would benefit from them.
  32. Review the latest prostate cancer clinical trials that resulted over the past year.